REGENERON PHARMACEUTICALS, INC. Inventory Write-down
REGENERON PHARMACEUTICALS, INC. (REGN) reported Inventory Write-down of $172.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-02-04
- REGENERON PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2022-12-31 was $157.40M, a 41.51% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2022-09-30 was $34.70M, a 10.34% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2022-06-30 was $19.20M, a 86.28% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2021-12-31 was $269.10M.
- REGENERON PHARMACEUTICALS, INC. inventory write-down for fiscal 2025 was $172.90M, a 36.90% increase from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. inventory write-down for fiscal 2024 was $126.30M, a 23.46% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. inventory write-down for fiscal 2023 was $102.30M, a 60.46% decline from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. inventory write-down for fiscal 2022 was $258.70M, a 43.40% decline from fiscal 2021.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month | Inventory Write-down 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $172.90M 10-K · filed 2026-02-04 | ||||
| 2024-12-31 | $126.30M 10-K · filed 2026-02-04 | ||||
| 2023-12-31 | $102.30M 10-K · filed 2026-02-04 | ||||
| 2022-12-31 | $157.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-05 | $192.10M derived: sum of 2 quarters · filed 2025-02-05 | $211.30M derived: sum of 3 quarters · filed 2025-02-05 | $258.70M 10-K · filed 2025-02-05 | |
| 2022-09-30 | $34.70M 10-Q · filed 2022-11-03 | $53.90M derived: sum of 2 quarters · filed 2022-11-03 | $101.30M 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | $19.20M 10-Q · filed 2022-08-03 | $66.60M 10-Q · filed 2022-08-03 | |||
| 2021-12-31 | $269.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | $307.80M derived: sum of 2 quarters · filed 2024-02-05 | $447.70M derived: sum of 3 quarters · filed 2024-02-05 | $457.10M 10-K · filed 2024-02-05 | |
| 2021-09-30 | $38.70M 10-Q · filed 2022-11-03 | $178.60M derived: sum of 2 quarters · filed 2022-11-03 | $188.00M 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $139.90M 10-Q · filed 2022-08-03 | $149.30M 10-Q · filed 2022-08-03 | |||
| 2020-12-31 | -$23.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | -$11.80M derived: sum of 2 quarters · filed 2023-02-06 | -$11.80M derived: sum of 3 quarters · filed 2023-02-06 | $0.00 10-K · filed 2023-02-06 | $39.20M 10-K · filed 2021-02-08 |
| 2020-09-30 | $11.80M 10-Q · filed 2021-11-04 | $11.80M derived: sum of 2 quarters · filed 2021-11-04 | $23.60M 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | $73.80M 10-K · filed 2022-02-07 | ||||
| 2018-12-31 | $12.50M 10-K · filed 2021-02-08 | ||||
| 2017-12-31 | $6.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $11.80M derived: sum of 2 quarters · filed 2020-02-07 | $14.50M derived: sum of 3 quarters · filed 2020-02-07 | $20.90M 10-K · filed 2020-02-07 | |
| 2017-09-30 | $5.40M 10-Q · filed 2017-11-08 | $8.10M derived: sum of 2 quarters · filed 2017-11-08 | $14.50M 10-Q · filed 2017-11-08 | $17.20M derived: sum of 4 quarters · filed 2017-11-08 | |
| 2017-06-30 | $2.70M 10-Q · filed 2017-08-03 | $9.10M 10-Q · filed 2017-08-03 | $11.80M derived: sum of 3 quarters · filed 2017-08-03 | $16.80M derived: sum of 4 quarters · filed 2017-11-08 | |
| 2017-03-31 | $6.40M 10-Q · filed 2017-05-04 | $9.10M derived: sum of 2 quarters · filed 2017-05-04 | $14.10M derived: sum of 3 quarters · filed 2017-11-08 | $16.10M derived: sum of 4 quarters · filed 2017-11-08 | |
| 2016-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $7.70M derived: sum of 2 quarters · filed 2017-11-08 | $9.70M derived: sum of 3 quarters · filed 2017-11-08 | $14.00M 10-K · filed 2017-02-09 | |
| 2016-09-30 | $5.00M 10-Q · filed 2017-11-08 | $7.00M derived: sum of 2 quarters · filed 2017-11-08 | $11.30M 10-Q · filed 2017-11-08 | $12.00M derived: sum of 4 quarters · filed 2017-11-08 | |
| 2016-06-30 | $2.00M 10-Q · filed 2017-08-03 | $6.30M 10-Q · filed 2017-08-03 | $7.00M derived: sum of 3 quarters · filed 2017-08-03 | $8.80M derived: sum of 4 quarters · filed 2017-08-03 | |
| 2016-03-31 | $4.30M 10-Q · filed 2017-05-04 | $5.00M derived: sum of 2 quarters · filed 2017-05-04 | $6.80M derived: sum of 3 quarters · filed 2017-05-04 | $13.20M derived: sum of 4 quarters · filed 2017-05-04 | |
| 2015-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $2.50M derived: sum of 2 quarters · filed 2017-02-09 | $8.90M derived: sum of 3 quarters · filed 2017-02-09 | $10.60M 10-K · filed 2017-02-09 | |
| 2015-09-30 | $1.80M 10-Q · filed 2016-11-04 | $8.20M derived: sum of 2 quarters · filed 2016-11-04 | $9.90M 10-Q · filed 2016-11-04 | $12.40M derived: sum of 4 quarters · filed 2017-02-09 | |
| 2015-06-30 | $6.40M 10-Q · filed 2016-08-04 | $8.10M 10-Q · filed 2016-08-04 | $10.60M derived: sum of 3 quarters · filed 2017-02-09 | $12.20M derived: sum of 4 quarters · filed 2017-02-09 | |
| 2015-03-31 | $1.70M 10-Q · filed 2016-05-05 | $4.20M derived: sum of 2 quarters · filed 2017-02-09 | $5.80M derived: sum of 3 quarters · filed 2017-02-09 | $6.60M derived: sum of 4 quarters · filed 2017-02-09 | |
| 2014-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $4.10M derived: sum of 2 quarters · filed 2017-02-09 | $4.90M derived: sum of 3 quarters · filed 2017-02-09 | $6.00M 10-K · filed 2017-02-09 | |
| 2014-09-30 | $1.60M 10-Q · filed 2015-11-04 | $2.40M derived: sum of 2 quarters · filed 2015-11-04 | $3.50M 10-Q · filed 2015-11-04 | $7.80M derived: sum of 4 quarters · filed 2016-02-11 | |
| 2014-06-30 | $800.00K 10-Q · filed 2015-08-04 | $1.90M 10-Q · filed 2015-08-04 | $6.20M derived: sum of 3 quarters · filed 2016-02-11 | $6.10M derived: sum of 4 quarters · filed 2016-02-11 | |
| 2014-03-31 | $1.10M 10-Q · filed 2014-05-08 | $5.40M derived: sum of 2 quarters · filed 2016-02-11 | $5.30M derived: sum of 3 quarters · filed 2016-02-11 | $7.00M derived: sum of 4 quarters · filed 2016-02-11 | |
| 2013-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $4.20M derived: sum of 2 quarters · filed 2016-02-11 | $5.90M derived: sum of 3 quarters · filed 2016-02-11 | $9.10M 10-K · filed 2016-02-11 | |
| 2013-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $1.60M derived: sum of 2 quarters · filed 2014-11-04 | $4.80M 10-Q · filed 2014-11-04 | $13.20M derived: sum of 4 quarters · filed 2015-02-12 | |
| 2013-06-30 | $1.70M 10-Q · filed 2014-08-05 | $4.90M 10-Q · filed 2014-08-05 | $13.30M derived: sum of 3 quarters · filed 2015-02-12 | $13.50M derived: sum of 4 quarters · filed 2015-02-12 | |
| 2013-03-31 | $3.20M 10-Q · filed 2013-05-03 | $11.60M derived: sum of 2 quarters · filed 2015-02-12 | $11.80M derived: sum of 3 quarters · filed 2015-02-12 | $18.30M derived: sum of 4 quarters · filed 2015-02-12 | |
| 2012-12-31 | $8.40M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $8.60M derived: sum of 2 quarters · filed 2015-02-12 | $15.10M derived: sum of 3 quarters · filed 2015-02-12 | $17.00M 10-K · filed 2015-02-12 | |
| 2012-09-30 | $200.00K 10-Q · filed 2012-10-24 | $6.70M derived: sum of 2 quarters · filed 2013-08-06 | $8.60M 10-Q · filed 2013-11-05 | ||
| 2012-06-30 | $6.50M 10-Q · filed 2013-08-06 | $8.40M 10-Q · filed 2013-08-06 | |||
| 2012-03-31 | $1.90M 10-Q · filed 2013-05-03 | ||||
| 2011-12-31 | $500.00K 10-K · filed 2014-02-13 | ||||
| 2010-12-31 | $0.00 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |